Search Close


Director Shareholdings

22nd July 2013

The Company has been informed that on 22 July 2013 certain Directors of the Company purchased ordinary shares in the Company as follows:


No. of Shares purchased

Price at which shares purchased

No. of shares held pursuant to transaction (% of ISC following transaction)

David Evans


31.8 pence



Kate Cornish-Bowden


32.0 pence



For Further Information:

Scancell Holdings Plc
Dr Richard Goodfellow, Joint CEO                     + 44 (0) 74 2323 0 497
Professor Lindy Durrant, Joint CEO

Cenkos Securities: 
Camilla Hume                     +44 (0) 20 7397 8900
Stephen Keys

FTI Consulting 
Simon Conway                   +44 (0) 20 7831 3113
Mo Noonan

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Tue, 20 Aug 2019 06:05:00

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00